Cutting Through the Hype to Successful Implementation and Impactful ROI
Boston, MA. October 9th, 2018 – The State Room
Partners
Partners
Key Features of AI in Pharma 2018
Where is AI Moving the Needle?
Understand how and where AI is having a genuine impact on R&D through use-case presentations at the cutting-edge of defining AI’s impact in pharma
Critical Strategic Discussions
Managing expectations, Demonstrating value internally, Responsibility of C-suite, Data infrastructure, Where to invest efforts and more will all be deciphered and analyzed
Senior-Level Networking
Meet with decision-makers and AI champions in this intimate and high-quality setting to generate genuinely impactful connections and takeaways
Members of the AI in Pharma Summit Community
Expert Speaker Faculty
Gayle M. Wittenberg, Ph.D. is Director of Integrated Solutions and Informatics, Janssen Neuroscience and Head of Translational Research & Precision Medicine, Research IT. She has lead Janssen’s mood informatics initiatives, bringing together the best available datasets with state of the art analytics to identify and profile different biological and phenotypic subtypes of Major Depression as candidates for targeted therapies. Her work analyzing immunology and oncology trials for improvements in depressive symptoms led in part to running a proof of concept study of an immunology compound in depressed patients. In her Research IT role, she is working to bring about a new era of analytics that is more inclusive of data and less siloed to drive us to answer our most important questions using ‘all the data in the world’. Dr. Wittenberg graduated summa cum laude with degrees in Physics and Electrical Engineering Physics at Oregon State University, and received her Ph.D. in Molecular Biology and Neuroscience at Princeton University where she studied computational neuroscience and learning in complex networks. She was a Princeton Council on Science and Technology Postdoctoral Teaching Fellow where she designed a new introductory biology course for physics and engineering students. She came to Janssen from Siemens Corporate Research where she headed the Personalized Healthcare group. While there, through mining genetic databases, she and her team designed PCR primers for the H1N1 flu within 3 days of the US outbreak, which outperformed those in use at the time. Previously she has worked at Trojan Nuclear Plant, installed the first computers used for electronic trading on the floor of the New York Stock Exchange working with Renaissance Technologies, spent a summer at Bell Labs recording birds singing in helium, and worked the salmon run in Naknek, Alaska.
Kim has been involved in large scale machine learning and medical informatics initiatives for over 15 years, over a range of ventures from computational drug design to disease risk prediction. He is currently the head of Artificial Intelligence for the Informatics department of Early Clinical Development at Genentech. Recently, he served as Chief Data Scientist at Lumiata, a predictive health analytics company. Kim received degrees from the University of Adelaide, and a PhD from the University of Melbourne (Australia). He was a Peter Doherty fellow and received postdoctoral training at the University of Cambridge and Stanford University. He then held leadership and consulting roles in the pharmaceutical and medical informatics industry, notably at Vertex. Following this, Kim worked extensively in online search at Discovery Engine (acquired by Twitter in 2009) and health informatics at Gliimpse (acquired by Apple in 2017).
John Baldoni is Senior Vice President, In silico Drug Discovery, in GSK Pharma R&D. This department employs in silico methods to identify patient needs, explore molecular interventions to address those needs and design and conduct clinical trials to test the medical hypothesis. Using these methodologies, the conventional empirical design make test cycle will be dramatically reduced. The intent is to discover medicines at higher velocity and with greater precision compared to current approaches. John is also Co-chair of ATOM, a public private partnership to advance the methodologies used to discover oncology medicines and put them in the public domain.
Jaquie is Head of Digital Health at Cambridge Consultants and leads the initiative to provide strategic guidance and practical support for clients transitioning their business model to include a digital element. These digital elements include device connectivity, data science, launch strategies, behavioural science and digital service design.
Jaquie has a BSc in Applied Biology, 10 years’ experience in Molecular Biology and 15 years’ experience of Product Management and Marketing for software, hardware and digital services in medical and life science industries that include immunology, ophthalmology, neuroscience and bioinformatics. Jaquie has also worked in telecommunications, food hygiene and intelligence informatics.
Jaquie is a member of the Chartered Institute of Marketing (CIM).
Dr Nora Khaldi is the Founder and Chief Scientific Officer of Nuritas, a groundbreaking tech company that accelerates medicine discovery using artificial intelligence (AI). Nora is a mathematician with a PhD in molecular evolution and has successfully led teams around the world in areas such as computational genomics and bioinformatics.
Recently joined the Alexion Data Sciences team to drive the orphan diseases knowledge base (data strategy & analytics) delivering drug target landscapes for R&D Strategy and clinical asset landscapes for Business Development deal flow. Currently working with children hospitals on a rare disease diagnostics playbook and algorithms. Prior to this, he built the Alexion EDM, Data Analytics & Decision Support capabilities which delivered MDM, Search, Content Analytics and a cloud-based data computing environment where the Data Science team and its external partners collaborate. Past roles include Head of Global Data Office at Biogen and Head of Global R&D Information Architecture practice at AstraZeneca.
Slava Akmaev, Ph.D. is the Senior Vice President and Chief Analytics Officer at BERG. Dr. Akmaev is an avid advocate for the application of Artificial Intelligence tools in healthcare. He developed the Bayesian Artificial Intelligence software, bAIcis™ and is a frequent speaker at Pharma and Digital Health meetings.
Pat Walters is VP of Computation at Relay Therapeutics in Cambridge, MA. His group focuses on novel applications of computational methods that integrate computer simulations and experimental data to provide insights that drive drug discovery programs. Prior to joining Relay, Pat spent more than 20 years at Vertex Pharmaceuticals where he was Global Head of Modeling & Informatics.
Sam helps organizations exploit innovations in artificial intelligence and develop novel capabilities. Working across drug discovery, clinical development and pharmaceutical manufacturing, he identifies transformative opportunities for data-driven decision-making, automation and development of disruptive approaches using technologies in artificial intelligence. As well as leading technical solutions in artificial intelligence projects, Sam develops and delivers training to businesses to leverage artificial intelligence and machine learning techniques, and enhance their internal capabilities.
Rachel Sha is the Vice President of Digital Business Development & Licensing at Sanofi. She leads a team of business development professionals in partnering, from identification to closing, across therapeutic areas and use cases in digital health with the goal of discovering, developing, and bringing to market solutions that improve outcomes, experience, at reduced costs. Companies she has led partnering deals with in digital include Verily Life Sciences, Science 37, and Evidation Health. Additionally, she serves on the Life Sciences Council of Springboard Enterprises which is focused on supporting women-led companies grow and expand.
Don Van Dyke is Chief Operating Officer at Cloud Pharmaceuticals. In his early career, he held increasingly responsible general management, business development, and executive positions at American Hospital Supply, Dade Diagnostics, Eastman Kodak and Millipore Corporation.
Van Dyke's work at the intersection of biological science and computer science began at startup Bio Image Corporation. The company became the market leader in image-based genomics and proteomics under his leadership as VP sales, VP worldwide marketing and sales, general manager, and CEO. The company merged with another firm and went public on the NASDAQ.
He has had executive roles at Molecular Mining Corporation, a life science data mining company and INCOGEN, a Bioinformatics company and has advised more than a dozen start-ups and government agencies. He has been a speaker at the Mason School of Business at the College of William and Mary and the Kenan-Flagler Business School at the University of North Carolina and is a graduate of Duke University.
Working closely with the National Cancer Institute Center for Biomedical Information and Information Technology (CBIIT) since 2014, Dr. Stahlberg currently leads several collaborative initiatives developing the capabilities and capacity to accelerate cancer research through expanded utilization of computational models, data science, and high-performance computing. He is program co-lead for the NCI-DOE collaboration for Joint Design of Advanced Computing Solutions for Cancer (JDACS4C) and provides key leadership in developing strategic collaborations, including with the Department of Energy. Working with DOE colleagues, he helped start the new public-private consortium for Accelerating Therapeutics for Opportunities in Medicine (ATOM) which aims to accelerate pre-clinical drug development with new levels of data, computation, collaboration across industry, academia and government. Prior to joining CBIIT, he led the formation of and directed the CCRIFX bioinformatics core supporting the several hundred scientists at the NCI Center for Cancer Research. His industry experience includes working for such companies as Cray Research, Oxford Molecular and Chemical Abstracts Service, where data and computation were integral to the success of each organization. Dr. Stahlberg received his BA from Wartburg College with majors in chemistry, computer science and mathematics, his PhD in Chemistry from The Ohio State University and held a post-doctoral appointment working at Argonne National Laboratory where he worked to advance the use of large scale computing in scientific applications.
Emmet holds 25+ years senior experience in some of the world’s largest Life-Science companies such as Pfizer, JNJ & Wyeth. He is well on the way making Nuritas the world’s largest discoverer of bioactive peptides and thus positively impacting global human health on a huge scale.
As Global Head of Drug Structure, Prediction & Design, Vanita supports drug discovery (small molecule and biologics) with a global team of computational chemists, structural biologists, protein engineers, and data scientists.
Lawrence Ganti is CEO|Americas of Innoplexus, an artificial intelligence based data analytics firm specializing in the lifesciences. Prior to joining Innoplexus, Lawrence spent 15 years leading teams across functions and geographies in the Pharmaceutical industry. He also worked as a research associate for McKinsey & Company and holds an MBA from IMD in Switzerland and a Bachelors from Babson College in the United States.
Dr. Birgit Schoeberl currently serves as a Global Head of Modeling and Simulation, PK Sciences at Novartis. Before joining Novartis, Birgit served as interim Senior Vice President, Scientific Value, at GNS Healthcare. During her time at GNS, she focused on applying causal machine learning to drug development. Prior to GNS, she was a member of the founding team at Merrimack Pharmaceuticals and where she spent over 12 years in different roles. In her latest role as Head of Discovery and Early Development, she gained broad experience in oncology drug discovery and development. Birgit and her leadership team were responsible for multiple preclinical and early clinical programs.
Birgit received her Chemical Engineering degree from the Technical University in Karlsruhe, Germany, and her Ph.D. in Biological Engineering from the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg. She was a post-doctoral fellow in the laboratories of Douglas Lauffenburger and Peter Sorger in the Biological Engineering Department at MIT.
Rupen drives PA’s AI and Automation work throughout R&D, primarily focusing on Regulatory, PV/Safety, and Clinical operations. Rupen also co-leads Business Design services in Life Sciences where he creates innovative business and IT architectures for PA’s life sciences clients.
Rupen has 20+ years of experience working with mid- to large-biopharmaceutical companies on operating model design, process improvement and automation, IT strategy / implementation, and information / data management. He specializes in large complex IT and business transformation programs.
As Director for the Translational Accelerator at Brigham and Women’s Hospital (Harvard University), Lena has created a clinical-stage accelerator to de-risk innovation and investments by supporting the transition of inventions with commercial potential from pre-clinical/prototype stage into first in patient.
As Director for Enabling technologies for Merck, Adam evaluates emergent technologies and their potential impact on Merck Business Units- specialism’s include: AI/data science, microbiome, vaccines, and biologics.
Physician scientist, mentor and team builder focused on bridging academic medicine and industry. Interested in solving problems relevant to human health and disease. Internationally recognized for work in molecular endocrinology and pharmacology with specialized expertise in the G protein-coupled receptor (GPCR) field.
Willem van Asperen brings fifteen years of experience in solving complex business issues by applying original thinking and a broad range of data analytics and artificial intelligence skills. He has developed predictive models that successfully take on the most difficult challenges: are we going to be in the press in the coming few days, looking at Twitter? Will that machine break down, looking at loggings? What is that clients' credit-worthiness, looking at their transactions? His insights where pivotal in assuring the quality of various major data analytics projects. He looks after PA's global data science and AI capability in The Netherlands, Denmark, Norway, United Kingdom, Germany and the USA. Clients that have worked with Willem are invariably enthusiastic about his insights and experience, and pragmatic, innovative approach and his drive and commitment.
Agenda
Click to download our full event agenda.
8:00 Registration, Breakfast & Networking
AI in Pharma: Cutting Through the Hype to Realization
Adoption of AI has been well underway in pharma over the last few years but critical discussions remain about how to best implement AI and extract the maximum amount of insights and value. This opening session will take a critical look at the strategic discussions and decisions that need to be made pharma to realize the full potential of AI. Utilise this session to go beyond the hype of AI in pharma and drill into the largest challenges and opportunities that face these applications today.
9:00 Chairman’s Opening Remarks & Setting the Scene
Sebastien Lefebvre, Senior Director, Data Analytics & Decision Support, Alexion Pharmaceuticals
9:10 A Machine Learning Enabled Workflow in Drug Discovery
John Baldoni, SVP, Head of In Silico Drug Discovery, GSK
9:35 Building the Digital Ecosystem Required for Tomorrow’s Clinical Trials
Jaquie Finn, Head, Digital Health, Cambridge Consultants
10:00 Panel Discussion and Open Q&A: Implementation to Realization – How do we Accelerate AI Through its Lifecycle in Pharma?
Birgit Schoeberl, Global Head, Modelling & Simulation, PK Sciences, Novartis
Gayle Wittenberg, Head, Translational Research and Precision Medicine Neuroscience Integrative Solutions & Pharma R&D IT, Janssen
Eric Stahlberg, Director, Biomedical Informatics and Data Science, Frederick National Laboratory
10:40 Morning Refreshments & Networking
Use Case Presentation I: Where is AI Moving the Needle?
AI holds huge promise in drug discovery and development but genuine examples of where these approaches are having an impact today remain sparse. This set of case-study presentations will showcase some of the most promising areas where AI is making an impact along the pharma workflow. Utilise these examples to understand how success has been achieved in these areas and what’s next for these promising research applications.
11:10 Use Case 1: Integrating Protein Motion and Machine Learning into the Drug Discovery Workflow
Pat Walters, Vice President, Computation, Relay Therapeutics
11:35 Use Case 2: The Use of AI in Early Clinical Development
Kim Branson, Head of A.I, Early Clinical Development Informatics, Genentech
12:00 Use Case 3: In Silico Predictions & In Vivo Correlations: The importance of Data Quality and Integrity in Driving AI empowered Discovery
Nora Khaldi, Founder & Chief Scientific Officer, Nuritas
12:25 Use Case 4: Can we Accelerate the Adoption of AI in Pharma by Learning from Experience in other Industries?
Sam Genway, Principal AI Solutions Engineer, Tessella
12:50 Long-Table Lunch & Networking
Interactive Workshops
During these intimate breakout sessions, attendees will discuss some of the key questions surrounding AI and machine learning in pharma. Through deep-dive discussions, examples and peer-to-peer learning, these interactive workshops will allow attendees to uncover answers to questions that are not possible through presentations and panels… The topics in session A and B will remain the same; giving you the opportunity to participate in two sessions. You are spoilt for choice!
1:50 Workshop Sessions A:
Workshop 1A:
Collaborating to Accelerate Drug Discovery: Lessons for Pharma and the Promise of AI in the Discovery of Next-Generation Therapeutics
Nuritas will run an interactive workshop with an insightful panel discussion on the topic
Vanita D. Sood, Global Head of Drug Structure, Prediction & Design, EMD Serono, Inc.
Agam Sheth, PhD, Director Enabling Technologies, Merck Research Laboratories, Merck & Co., Inc.
Alan Kopin, Director, Molecular Pharmacology Research Center | Professor, Tufts University School of Medicine | Professor, Sackler School of Graduate Biomedical Sciences
Lina Williamson, DVM PhD, Director, Entrepreneurship & Innovation | Translational Accelerator, Brigham and Women’s Hospital (Harvard University)
John Baldoni, SVP, Head of In Silico Drug Discovery, GSK
Nora Khaldi, Founder & Chief Scientific Officer, Nuritas
Emmet Browne, Chief Executive Officer, Nuritas
Workshop 2A:
Practical & Relevant applications of Artificial Intelligence
Why do so many companies fail in delivering AI & Machine Learning tools to the Pharma? Learn about some key elements to consider when considering the use of AI and ML in Pharma including some high level, practical use cases.
Lawrence Ganti, CEO of Life Sciences, Innoplexus
2:30 Workshop Sessions B: Time to Switch!
Workshop 1B:
Collaborating to Accelerate Drug Discovery: Lessons for Pharma and the Promise of AI in the Discovery of Next-Generation Therapeutics
Nuritas will run an interactive workshop with an insightful panel discussion on the topic
Vanita D. Sood, Global Head of Drug Structure, Prediction & Design, EMD Serono, Inc.
Agam Sheth, PhD, Director Enabling Technologies, Merck Research Laboratories, Merck & Co., Inc.
Alan Kopin, Director, Molecular Pharmacology Research Center | Professor, Tufts University School of Medicine | Professor, Sackler School of Graduate Biomedical Sciences
Lina Williamson, DVM PhD, Director, Entrepreneurship & Innovation | Translational Accelerator, Brigham and Women’s Hospital (Harvard University)
John Baldoni, SVP, Head of In Silico Drug Discovery, GSK
Nora Khaldi, Founder & Chief Scientific Officer, Nuritas
Emmet Browne, Chief Executive Officer, Nuritas
Workshop 2B:
Practical & Relevant applications of Artificial Intelligence
Why do so many companies fail in delivering AI & Machine Learning tools to the Pharma? Learn about some key elements to consider when considering the use of AI and ML in Pharma including some high level, practical use cases.
Lawrence Ganti, CEO of Life Sciences, Innoplexus
3:10 Afternoon Refreshments
Use Case Presentations II: Where is AI Moving the Needle?
AI holds huge promise in drug discovery and development but genuine examples of where these approaches are having an impact today remain sparse. This set of case-study presentations will showcase some of the most promising areas where AI is making an impact along the pharma workflow. Utilise these examples to understand how success has been achieved in these areas and what’s next for these promising research applications.
3:40 Use Case 5: Deep Learning Applied to Crystal Structural Imaging
Vijay Bulusu, Head, Data & Digital Innovation, Pfizer
4:05 Use Case 6: AI in Action: Four Ways We’re Using AI Right Now in Pharma
Rupen Mehta, Life Sciences Expert, PA Consulting Group
Willem van Asperen, Global Capability Lead AI & Data Analytics, PA Consulting Group
Looking Ahead and Critical Questions
With many learnings from this summit and a vast number of options moving forward, it is crucial that pharma takes a critical look at how to utilize AI moving forward. This closing panel session will focus on the crucial questions pharma needs to ask itself and collaborators in relation to where and how to best invest efforts and resources. Utilize this session to finalize genuine takeaways from the event around the crucial challenges/opportunities that remain.
4:30 Panel Discussion and Open Q&A: How and Where Should we Invest our Efforts Moving Forward?
Don Van Dyke, Chief Operating Officer, Cloud Pharmaceuticals
Slava Akmaev, Senior Vice President & Chief Analytics Officer, Berg Health
Kim Branson, Head of A.I, Early Clinical Development Informatics, Genentech
Rachel Sha, Vice President, Digital Business Development, Sanofi
5:10 Chair’s Closing Remarks
Sebastien Lefebvre, Senior Director, Data Analytics & Decision Support, Alexion Pharmaceuticals
5:20 Drinks Reception
6:20 Close of 2nd Annual AI in Pharma Summit
The Venue
The AI in Pharma Summit takes place in the inspiring State Room, situated on the 33rd Floor of the Sixty State Street skyscraper in downtown Boston.
Panoramic windows, mahogany floors and state of the art lighting ensure that this purpose built venue will enhance your learning experience.
We’ve worked closely with our caterers to ensure you have everything you need for the day. From brain fuel at the innovation breakfast to relaxing drinks at the end of the day, everything is designed to enhance your experience.
Accommodation is not available at the venue, but there is a wide variety of hotels within short walking distance.
Full details of the venue location, hotels, catering and travel will be included in your registration pack.
Registration
Sponsorship
The 2017 summit exceeded all expectations and the 2018 summit is attracting considerable interest.
The success of the 2017 summit was down to the high-class programme and the quality of the audience. Registrations were only accepted from applicants who were appropriate for the summit and delegates from vendor companies were not permitted.
This ensured that the audience of senior decision makers were able to meet with a selected group of relevant suppliers. Our 2017 sponsors tell us that they made significant inroads into target companies and advanced their sales pipelines.
For further information, or to have an informal discussion regarding sponsorship opportunities, please contact Sam Confino on 020 3865 9002 or sam@greygreenmedia.com
2017 Audience Breakdown
2017 Audience Job Title
Register For The Event
For pricing and booking options please click the button to go to the registration page.
Registration
